Cargando…
Biological Insights into Chemotherapy Resistance in Ovarian Cancer
The majority of patients with high-grade serous ovarian cancer (HGSOC) initially respond to chemotherapy; however, most will develop chemotherapy resistance. Gene signatures may change with the development of chemotherapy resistance in this population, which is important as it may lead to tailored t...
Autores principales: | Glasgow, Michelle A., Argenta, Peter, Abrahante, Juan E., Shetty, Mihir, Talukdar, Shobhana, Croonquist, Paula A., Khalifa, Mahmoud A., Starr, Timothy K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547356/ https://www.ncbi.nlm.nih.gov/pubmed/31052165 http://dx.doi.org/10.3390/ijms20092131 |
Ejemplares similares
-
Mesenchymal Stem Cells As Guideposts for Nanoparticle-Mediated Targeted Drug Delivery in Ovarian Cancer
por: Layek, Buddhadev, et al.
Publicado: (2020) -
Incisional carcinoma of Mullerian Origin: A case report and review of literature
por: Bedell, Sabrina, et al.
Publicado: (2020) -
Long term follow-up of a phase II trial of multimodal therapy given in a “sandwich” method for stage III, IV, and recurrent endometrial cancer
por: Glasgow, Michelle, et al.
Publicado: (2016) -
GLS1 is a Protective Factor in Patients with Ovarian Clear Cell Carcinoma and its Expression Does Not Correlate with ARID1A-mutated Tumors
por: Clemente, Valentino, et al.
Publicado: (2022) -
Ovarian Cancer Stemness: Biological and Clinical Implications for Metastasis and Chemotherapy Resistance
por: Motohara, Takeshi, et al.
Publicado: (2019)